Leslie Burgess, MA

Leslie Burgess is a writer and member of the American Medical Writers Association living in Southern California. She has been working in the fields of science and medicine for more than 20 years and holds a BS in journalism from Monmouth University. Leslie is a volunteer for California State Parks and an avid photographer.

Most Recent Articles by Leslie Burgess, MA

Lower Cabazitaxel Dose May Benefit Patients With Prostate Cancer

Lower Cabazitaxel Dose May Benefit Patients With Prostate Cancer

By

The lesser toxicity of the 20 mg/m2 dose compared with the 25 mg/m2 dose may benefit frail patients in particular, or those with poor functional status.

In Focus: Abemaciclib for Advanced Breast Cancer

In Focus: Abemaciclib for Advanced Breast Cancer

By

Several presentations demonstrated that abemaciclib provides clinical benefit for women with HR+/HER2-negative breast cancer who progress on or are resistant to endocrine therapy.

Q&A With Keith Flaherty, MD: Dabrafenib and Trametinib for Melanoma

Q&A With Keith Flaherty, MD: Dabrafenib and Trametinib for Melanoma

By

Cancer Therapy Advisor interviewed Keith Flaherty, MD, about recent findings regarding targeted therapies for melanoma.

Random Mutations May Be Leading Cause of Oncogenesis

Random Mutations May Be Leading Cause of Oncogenesis

By

According to a study across all 32 cancer types, data suggest that 66% of mutations leading to cancer are the result of random events.

Ibrutinib Improves PFS vs Temsirolimus in Patients With Mantle Cell Lymphoma

Ibrutinib Improves PFS vs Temsirolimus in Patients With Mantle Cell Lymphoma

By

Patients with relapsed or refractory MCL treated with ibrutinib had longer PFS with less toxicity than patients treated with temsirolimus in a phase 3 trial.

More Articles by Leslie Burgess, MA

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters